<unk>  (formerly torezolid, trade name Sivextro), is an oxazolidinone-class antibiotic.<unk>  phosphate is a phosphate ester prodrug of the active compound<unk> . It was developed by Cubist Pharmaceuticals, following acquisition of Trius Therapeutics (originator: Dong-A Pharmaceuticals), and is marketed for the treatment of acute bacterial skin and skin structure infections (also known as complicated skin and skin-structure infections (cSSSIs)). The most common side effects include nausea (feeling sick), headache, diarrhoea and vomiting. These side effects were generally of mild or moderate severity.<unk>  was approved for medical use in the United States in June 2014, and for medical use in the European Union in March 2015.
Tedizolid
Telithromycin
Roxithromycin
Azithromycin
Dirithromycin
Rifampicin
Cadazolid
Gemifloxacin